DavidA.GorelickMD

Addiction

Professor of Psychiatry, University of Maryland School of Medicine Editor-in-Chief, Journal of Cannabis Research

Dr. Gorelick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
5500 Nathan Shock Dr
Baltimore, MD 21224
Phone+1 410-550-1478

Fax+1 410-550-1528

David Gorelick, MD is a psychiatrist based in Baltimore, MD with a subspecialty in addiction. His medical training was completed at the Albert Einstein College of Medicine and residency at the UCLA David Geffen School of Medicine/UCLA Medical Center. He currently serves as a professor at the University of Maryland School of Medicine, editor-in-chief of the Journal of Cannabis Research, and a member of the Maryland Cannabis Public Health Advisory Council. Dr. Gorelick has published more than 200 papers in peer-reviewed medical journals and has designed and conducted numerous phase I and II clinical trials related to addiction and its treatmt. His work focuses on treatment of substance use disorders and comorbidity with other psychiatric disorders, such as schizophrenia.

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 1977 - 1980
UCLA-VA Greater Los AngelesInternship, Internal Medicine, 1976 - 1977
Albert Einstein College of MedicineClass of 1976

PubMed

4 citations
Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.
Deanna L Kelly, Matthew Glassman, Ikwunga Wonodi, Gopal Vyas, Charles M Richardson
Schizophrenia Research. 2024-06-01
6 citations
Cannabis-Related Disorders and Toxic Effects.
David A Gorelick
The New England Journal of Medicine. 2023-12-14
5 citations
A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder.
Chamindi Seneviratne, David A Gorelick, Kevin G Lynch, Clayton Brown, Danielle Romer
Alcoholism, Clinical and Experimental Research. 2022-10-01

Other

Cocaine abuse and dependence in adults
Gorelick DA
http://www.uptodate.com/contents/cocaine-abuse-and-dependence-in-adults
UpToDate, Wolters Kluwer Health - 2011-12-19

Legalization of Marijuana Could Lead to Public Health Concerns, Study SuggestsJanuary 1st, 2020
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid DependenceJuly 27th, 2006
Stop Smoking Now!! See the 9 Side Effects of MarijuanaFebruary 25th, 2017
Join now to see all

Identification Of Factors Associated With Response To Drugs And TreatmentNational Institute On Drug Abuse2009–2010
Development Of New Pharmacologic And Biologic Treatments For Drug DependenceNational Institute On Drug Abuse2009–2010
Development Of New Pharmacologic And Biologic Treatments For Drug DependenceNational Institute On Drug Abuse2007–2008
Identification Of Factors Associated With Response To Drugs And TreatmentNational Institute On Drug Abuse1993–2008
Development Of New Pharmacologic And Biologic TreatmentsNational Institute On Drug Abuse2006
Identification Of Factors Associated With Response To DRNational Institute On Drug Abuse2002–2006
Identification Of Factor Associated W/ Response To DrugsNational Institute On Drug Abuse2005
Development Of New Pharmacologic And Biologic TreatmentsNational Institute On Drug Abuse2003–2005
Development Of New Pharmacologic And Biologic TreatmentNational Institute On Drug Abuse2002
New Treatment For Drug DependenceNational Institute On Drug Abuse2001
Factors Associated With Response To Drugs And TreatmentNational Institute On Drug Abuse2001
Development Of New Pharmacologic And Biologic Treatment For Drug DependenceNational Institute On Drug Abuse1993–2000